Vireo Growth Revenue Growth Rates (VREOF), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vireo Growth Inc.  (OTC: VREOF)
 

VREOF's Revenue Growth by Quarter and Year

Vireo Growth's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VREOF Revenue (in millions $) FY 2027 FY 2026 FY 2025 FY 2024
4th Quarter December -
3rd Quarter September -
2nd Quarter June 209.30
1st Quarter March 106.20
FY 315.50

VREOFs Annual Revenue
Vireo Growth's Revenue in the fiscal year 2025 $ 268.77 millions
Vireo Growth's Revenue in the fiscal year 2024 $ 99.38 millions
Vireo Growth's Revenue in the fiscal year 2023 $ 88.13 millions
Vireo Growth's Revenue in the fiscal year 2022 $ 74.63 millions
Vireo Growth's Revenue in the fiscal year 2021 $ 49.21 millions




VREOF Revenue second quarter 2027 Y/Y Growth Comment
Vireo Growth Inc. achieved in the second quarter 2027, above Company average Revenue surge of 335.5% year on year, to $ 209.30 millions.

According to the results reported in the second quarter 2027, Vireo Growth Inc. achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Vireo Growth Inc.' s Revenue doubling of 335.5% ranks overall at the positon no. 0 in the second quarter 2027.


VREOF Revenue ( Y/Y Growth %) 2027
 2026 2025 2024
4th Quarter December - 317.87 % 3.52 % 26.94 %
3rd Quarter September - 264.16 % 1.99 % 30.93 %
2nd Quarter June 335.5 % 91.4 % 24.31 % -4.22 %
1st Quarter March 333.47 % 1.7 % 26.19 % 22.06 %
FY   - 170.42 % 12.76 % -

Financial Statements
Vireo Growth's second quarter 2027 Revenue $ 209.30 millions VREOF's Income Statement
Vireo Growth's second quarter 2026 Revenue $ 48.06 millions Quarterly VREOF's Income Statement


VREOF Revenue (Quarter on Quarter Growth %)

 2027
 2026 2025 2024
4th Quarter December - 14.06 % -0.6 % -2.07 %
3rd Quarter September - 90.72 % 0.24 % 22.18 %
2nd Quarter June 97.08 % 96.16 % 4.23 % 5.81 %
1st Quarter March 1.58 % -2.08 % -0.33 % 0.26 %
FY (Year on Year)   - 170.42 % 12.76 % -


Back to VREOF Growth rate Comparisons >> Back to VREOF Growth rate Comparisons >>


Revenue second quarter 2027 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #0

Revenue Y/Y Growth Statistics
High Average Low
335.47 % 75.71 % -4.24 %
(Jun 30 2026)   (Mar 31 2025)
Revenue second quarter 2027 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #0
Revenue Y/Y Growth Statistics
High Average Low
335.47 % 75.71 % -4.24 %
(Jun 30 2026)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2024, 2025, 2026, 2027

Vireo Growth's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
97.08 % 15.19 % -10.6 %
(Jun 30 2026)  


VREOF's II. Quarter Q/Q Revenue Comment
Vireo Growth Inc. achieved in the II. Quarter 2027 above company average sequential Revenue jump of 97.08%, to $ 209.30 millions, from $106.20 millions in the first quarter.
VREOF is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry Vireo Growth Inc. achieved highest sequential Revenue growth. While Vireo Growth's Revenue growth quarter on quarter, overall rank is 0.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Statistics
High Average Low
97.08 % 15.19 % -10.6 %
(Jun 30 2026)  


VREOF's II. Quarter Q/Q Revenue Comment
Vireo Growth Inc. achieved in the II. Quarter 2027 above company average sequential Revenue jump of 97.08%, to $ 209.30 millions, from $106.20 millions in the first quarter.
VREOF is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry Vireo Growth Inc. achieved highest sequential Revenue growth. While Vireo Growth's Revenue growth quarter on quarter, overall rank is 0.


Vireo Growth's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 511.71 $ 350.47 $ 268.77 $ 189.24 $ 122.75
Y / Y Revenue Growth (TTM) 316.86 % 251.18 % 170.43 % 92.06 % 25.2 %
Year on Year Revenue Growth Overall Ranking # 77 # 132 # 174 # 581 # 1542
Seqeuential Revenue Change (TTM) 46.01 % 30.4 % 42.02 % 54.17 % 23 %
Seq. Revenue Growth (TTM) Overall Ranking # 77 # 132 # 174 # 581 # 1542


Cumulative Revenue growth Comment
With 316.86% annual Revenue growth, Vireo Growth Inc. would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

Vireo Growth Inc. achieved highest trailing twelve month year on year Revenue growth. While Total ranking has impoved so far to 77, from total ranking in previous quarter at 132.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
316.86 %
 60.52 %
7.16 %
(Jun 30 2026)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 # 0
Cumulative Revenue growth Comment
With 316.86% annual Revenue growth, Vireo Growth Inc. would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

Vireo Growth Inc. achieved highest trailing twelve month year on year Revenue growth. While Total ranking has impoved so far to 77, from total ranking in previous quarter at 132.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
316.86 %
60.52 %
7.16 %
(Jun 30 2026)  






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VREOF's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions
Kymera Therapeutics Inc 466.40%$ 466.399 millions
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions


About Vireo Growth Revenue Growth Rates (VREOF), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vireo Growth Inc (CIK 1771706).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-097118
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vireo Growth Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.